The Rise of Synaptic Density PET Imaging

Area of Science:

• Neuroscience
• Radiochemistry
• Medical Imaging

Background:

• Neurological disorders often involve synaptic loss or dysfunction.
• Traditional synaptic quantification methods required post-mortem or surgical tissue samples.
• Electron microscopy and immunohistochemistry were historical gold standards for synaptic analysis.

Purpose of the Study:

• To review the development of positron emission tomography (PET) radiotracers for synaptic vesicle 2A protein.
• To discuss the preclinical and clinical applications of these in vivo synaptic imaging agents.
• To highlight the perspectives and limitations of current PET tracers for synaptic quantification.

Main Methods:

• Development of PET radiotracers using Carbon-11 (¹¹C) and Fluorine-18 (¹⁸F).
• Preclinical validation in rodent and non-human primate models.
• Application of various kinetic modeling methods for binding quantification.
• Review of radiochemical strategies, preclinical proof-of-concept, and clinical outcomes.

Main Results:

• Several PET radiotracers targeting synaptic vesicle 2A protein have been successfully developed.
• These tracers allow for in vivo visualization and quantification of synapses.
• Preclinical studies demonstrated proof-of-concept, and initial clinical outcomes are emerging.

Conclusions:

• PET imaging of synaptic vesicle 2A protein offers a non-invasive method for assessing synaptic integrity in vivo.
• This technology holds significant promise for understanding and diagnosing neurological disorders.
• Further research is needed to fully realize the potential and address limitations of these PET tracers.